Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Prostate Cancer With DNA Repair Defects
NCT03040791Phase 2Unknown
- Sponsor
- Hospital Moinhos de Vento
- Start
- Jun 2018
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hospital Moinhos de Vento. Status: unknown.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03040791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040791.